A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Heo, Jeong | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Woo, Hyun Young | - |
dc.contributor.author | Lee, Heon Ju | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Yoon, Ki Tae | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Kim, Chang Wook | - |
dc.contributor.author | Kim, Hyung Hoi | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Cho, Mong | - |
dc.date.accessioned | 2021-09-04T01:05:29Z | - |
dc.date.available | 2021-09-04T01:05:29Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89072 | - |
dc.description.abstract | Background and Aim:There are limited data assessing whether patients who achieved virological suppression on lamivudine but remain hepatitis B e antigen-positive should be switched to a more potent antiviral with a high genetic barrier to resistance or continue with lamivudine. We compared the safety and efficacy of switching with entecavir versus continuing lamivudine. Methods:This was a Phase IV, randomized, open-label, prospective study in a tertiary care setting. Seventy-three chronic hepatitis B patients who achieved virological suppression on lamivudine (serum hepatitis B virus DNA<60International Unit (IU)/mL) were enrolled. Entecavir or lamivudine were administered orally for up to 96weeks. Virologic and serologic responses were measured throughout the study. Results:A significantly higher proportion of patients in the entecavir group achieved hepatitis B virus DNA<60IU/mL at Weeks 48 (100% [38/38] vs 62.8% [22/35]; P<0.001) and 96 (97.4% [37/38] vs 57.1% [20/35]; P<0.001). A greater number of patients had virologic breakthrough (Week 96 cumulative incidence 42.9% vs 2.6%; P<0.001) and genotypic lamivudine resistance (28.6% [10/35] vs 0% [0/38]; P<0.001) in the lamivudine group. No serious adverse events or laboratory abnormalities were reported. Conclusions:Even after achieving virological suppression on lamivudine therapy, the risk of emergent lamivudine resistance increases over time. Switching to entecavir resulted in a maintained virologic response and superior serologic responses versus continued lamivudine therapy. This study supports a rationale for switching to entecavir in chronic hepatitis B patients with virological suppression on lamivudine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | CHRONIC HEPATITIS-B | - |
dc.subject | VIRUS GENOTYPE | - |
dc.subject | INFECTION | - |
dc.subject | RESISTANT | - |
dc.title | A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.1111/jgh.13231 | - |
dc.identifier.scopusid | 2-s2.0-84963877913 | - |
dc.identifier.wosid | 000374702700027 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, v.31, no.4, pp.865 - 871 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.title | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.citation.volume | 31 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 865 | - |
dc.citation.endPage | 871 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-B | - |
dc.subject.keywordPlus | VIRUS GENOTYPE | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordAuthor | entecavir | - |
dc.subject.keywordAuthor | hepatitis B | - |
dc.subject.keywordAuthor | lamivudine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.